News
Latest mentions of Lucius Partners, Laidlaw & Company, and Jimmy Ahern online
- August 17, 2023
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, in Collaboration with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Announces $5.88 Million Award from the U.S. Department of Defense
Unveiling the BRiTE Future of Oncological BioTech with James Ahern of Laidlaw & Company
- July 6, 2023
The Egyptians were the first to diagnose cancer, 5,000 years ago. But their understanding of the disease was rudimentary at best, and they had no effective treatments. It wasn’t until the mid-1700s that doctors first attempted surgery on early-stage tumors. Pity the poor patients – it was almost a century before the first anesthetics. Marie Curie’s ground-breaking research led to the first use of radiotherapy in 1900. Forty years later doctors treating soldiers who had been exposed to mustard gas realized the treatment they were using was effective against cancer. And so, chemotherapy was born.
Lucius Partners Portfolio Company Algorithm Sciences, Inc. Completes the Purchase of Flowonix Assets (Prometra II Pump)
- June 26, 2023
Lucius Partners, LLC today announced that its portfolio company, Algorithm Sciences, Inc. (Algorithm), has competed the purchase of all assets of Flowonix Medical, Inc. The transaction was a simple asset purchase; Algorithm did not acquire the liabilities or the corporate entity of Flowonix.
Lucius Partners Portfolio Company PD Theranostics, Inc. Signs Letter of Intent to Merge with Fulton Ventures Corp.
- March 07, 2023
Lucius Partners, LLC today announced that its portfolio company, PD Theranostics, Inc. (“PDTx“), has signed a non-binding letter of intent (the “LOI“) to combine with Fulton Ventures Corp. (“Fulton“), a company incorporated in British Columbia, Canada.
Voltron Therapeutics, Inc. Announces Sponsored Research Agreement With the Massachusetts General Hospital, Harvard Medical School, To Initiate a Pre-Clinical Immuno-Oncology Trial
- March 6, 2023
Voltron Therapeutics, Inc, a Lucius Partners portfolio company, announced today that it has signed a new Sponsored Research Agreement (SRA) with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
Lucius Partners Announces the Addition of Centaur Bio, Inc. to the Portfolio
- Feb 03, 2023
Lucius Partners, LLC announced the addition of Centaur Bio, Inc. to the company’s portfolio. Centaur’s novel technology was originally developed by researchers in the Department of Neurosurgery at Duke University, led by Dr. John H. Sampson, the Robert H. and Gloria Wilkins Distinguished Professor and Chair of the Department of Neurosurgery. This novel technology facilitates transport of therapeutics to any tissue of interest, including the brain, potentially generating improved treatments for solid tumors and CNS disorders.
Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial
- Feb 28, 2023
Voltron Therapeutics, Inc, a Lucius Partners portfolio company, announced today that it has signed a new Sponsored Research Agreement (SRA) with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.
James Ahern of Laidlaw Venture Partners Joins with Naples Redevelopment Group on New Real Estate Project
- Dec 13, 2022
Laidlaw Venture Partners, a private equity financing and accelerating arm of Laidlaw & Company (UK) Ltd., is pleased to announce their participation in a new real estate project in Naples, Florida, “The Mark on 8th.” Acting as a financial partner, Laidlaw contributed 11.6 million dollars in capital alongside Naples Redevelopment Group.
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium
- Oct 26, 2022
The MHSRS is the Department of Defense’s largest scientific meeting and is designed to highlight new scientific approaches to address DoD research priorities. Military leaders, academic researchers, and industry present and collaborate on research / health care initiatives falling under numerous topic areas including Military Infectious Diseases.
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study
- Jul 14, 2022
NEW YORK, July 14, 2022 /PRNewswire/ — Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers. This is a well-validated murine model of HPV related cancers.
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor
- Jul 12, 2022
NEW YORK, July 12, 2022 /PRNewswire/ — Voltron Therapeutics, Inc. today announced that life science veteran, Dr. Tony Hodges, has joined the Company as Senior Scientific Advisor.
Dr. Hodges brings a wealth of experience in Transplant Medicine, Infectious Disease and clinical trials to help guide further development, and eventual commercialization, of products leveraging its Self-Assembling Vaccine (SAV) platform.
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
- June 30, 2022
Lucius Partners, LLC has reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model. This study, if successful, may support filing of an Investigational New Drug (IND) application with the US Food and Drug Administration.
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology Lucius Partners Logo
- Jun 23, 2022
NEW YORK, June 23, 2022 /PRNewswire/ — Lucius Partners, LLC today reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model. This study, if successful, may support filing of an Investigational New Drug (IND) application with the US Food and Drug Administration.
James Ahern Leads Laidlaw Venture Partners to Secure PIPE Financing for Odyssey Laidlaw Company Logo
- Jun 08, 2022
Pairing to Facilitate Odyssey Concussion Study and Enhance Shareholder Value
New York , June 8, 2022 /PRNewswire/ — Health-tech focused venture capital firm, Laidlaw Venture Partners is pleased to announce it has secured PIPE financing for Odyssey Group, one of the world’s leading providers of reinsurance.
Jimmy Ahern Serves as Vice Chair for 7th Year as Laidlaw Sponsors Big Brothers Big Sisters Golf Classic 2022 to Raise $1 Million
- Jun 06, 2022
Boston , June 6, 2022 /PRNewswire/ — New York-based venture capital firm, Laidlaw Capital Markets was honored to sponsor the world’s largest mentorship network, Big Brothers Big Sisters of Eastern Massachusetts for its keystone fundraiser.
Algorithm Sciences, a Laidlaw Venture Partners Portfolio Company, Announces Key Management Appointments
- September 15, 2021
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced key management appointments for its portfolio company, Algorithm Sciences, Inc.
Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
- Jun 24, 2020
Amesite Inc. Closes $5.5 Million Financing and Go-Public Transaction
- June 14, 2018
Company Developing an AI Powered Online Platform for Colleges and Universities
Laidlaw Venture Partners Portfolio Company AerWave Medical, Inc. Closes $4 Million Series A Financing Round
- February 24, 2021
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave.
